

Current Report No 31

Acceleration of the Genomtec® ID platform commercialization and signing up loan agreements in connection to financing of the fast-tracked project activities.

The Management Board of Genomtec S.A. based in Wrocław ("Issuer", "Company"; "Borrower") hereby announces that on 24 December 2021, it entered into loan agreements with the right to acquire shares with natural persons ("Lenders"). Under the above-mentioned agreements, the Company has raised a total of PLN 2.9 million for implementation of the Company's strategy to accelerate commercialisation of the Genomtec® ID platform.

The Loans may be repaid as follows:

- i. in the form of a cash repayment due by 31 December 2022, with the repayment term reserved for the benefit of the Borrower, i.e. the Borrower has the right to repay earlier part of it or all of the loans
- ii. in the form of subscription for Borrower's new issue of shares by the Lenders (the "Share Subscription Right"). Repayment of the Loan based on the Right to Take Up Shares is a right of the Borrower, i.e. the Company has the right to repay the Loan based on the Right to Take Up Shares and, if the Borrower declares to exercise this right, the Borrower and the Lenders agree to carry out the repayment based on the Right to Take Up Shares. Under the Share Subscription Right, the Lenders shall be entitled for subscription of such number of shares in the Company as shall be quotient of: (a) the amount of the Loan paid and not repaid, together with interest due, and (b) the issue price calculated as the volume-weighted average price of Genomtec shares on the NewConnect stock exchange market for the last 3 months since the date of the Loan Agreement, reduced by 20%.

The analysis of the possible planned acceleration of the Genomtec® ID platform commercialisation, which the Company announced in ESPI Current Report No. 27/2021 on 3 November 2021, showed that due to the postponement in the implementation of the IVDR Directive, the ideal time for market entrance of the Genomtec® ID platform would be the second half of the next year, which presents a acceleration of the communicated plan since then. It becomes possible by advantageous product certification under the current directive (IVDD and not IVDR as previously planned) thus allowing for quicker sales revenue generation.



The IVDR certification will be executed at a later stage after the Genomtec® ID is launched on the market. The aforementioned activities are aimed at fast-tracking Company's growth and its scale of operations, taking advantage of the market situation, legal environment and the Company's know-how.

Provision of funds supporting accelerated commercialisation of the Company's flagship solution, the Genomtec ID platform, is an important event for the Company's operations and, in the opinion of the Management Board, in the opinion of the Management Board, this information meets the criteria of confidential information within the meaning of Art. 7 sec. 1 MAR.